Validation study of risk-reduction activities after personalized breast cancer education tool in the WISDOM study.

IF 6.5 2区 医学 Q1 ONCOLOGY NPJ Breast Cancer Pub Date : 2024-10-14 DOI:10.1038/s41523-024-00681-z
Tianyi Wang, Mandy Che, Yash S Huilgol, Holly Keane, Deborah Goodman, Rashna Soonavala, Elissa Ozanne, Yiwey Shieh, Jeffrey K Belkora, Allison Stover Fiscalini, Laura J Esserman
{"title":"Validation study of risk-reduction activities after personalized breast cancer education tool in the WISDOM study.","authors":"Tianyi Wang, Mandy Che, Yash S Huilgol, Holly Keane, Deborah Goodman, Rashna Soonavala, Elissa Ozanne, Yiwey Shieh, Jeffrey K Belkora, Allison Stover Fiscalini, Laura J Esserman","doi":"10.1038/s41523-024-00681-z","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer risk reduction strategies have been well-validated, but barriers remain for high-risk individuals to adopt them. We performed a study among participants with high risk of breast cancer to validate whether a virtual breast health decision tool impacted a participant's willingness to start risk-reducing activities, identify barriers to adopting these strategies, and understand if it affects breast cancer anxiety. The study sample was 318 participants in the personalized (investigational) arm of the Women Informed to Screen Depending on Measures of risk (WISDOM) clinical trial. After reviewing the tool, these participants completed a feedback survey. We demonstrated that 15 (4.7%) women were taking endocrine risk reduction, 123 (38.7%) were reducing alcohol intake, and 199 (62.6%) were exercising. In the three-month follow-up survey of 109 respondents, only 8 of 61 (13.1%) women who considered endocrine risk reduction pursued it. In contrast, 11 of 16 (68%) participants who considered alcohol reduction pursued the activity, and 14 of 24 (58%) women who considered exercise followed through. Participants listed fear of side effects as the most common barrier to endocrine risk reduction. We also present further steps to be taken to improve the effectiveness of the Breast Health Decisions tool.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"10 1","pages":"90"},"PeriodicalIF":6.5000,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11471852/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Breast Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41523-024-00681-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Breast cancer risk reduction strategies have been well-validated, but barriers remain for high-risk individuals to adopt them. We performed a study among participants with high risk of breast cancer to validate whether a virtual breast health decision tool impacted a participant's willingness to start risk-reducing activities, identify barriers to adopting these strategies, and understand if it affects breast cancer anxiety. The study sample was 318 participants in the personalized (investigational) arm of the Women Informed to Screen Depending on Measures of risk (WISDOM) clinical trial. After reviewing the tool, these participants completed a feedback survey. We demonstrated that 15 (4.7%) women were taking endocrine risk reduction, 123 (38.7%) were reducing alcohol intake, and 199 (62.6%) were exercising. In the three-month follow-up survey of 109 respondents, only 8 of 61 (13.1%) women who considered endocrine risk reduction pursued it. In contrast, 11 of 16 (68%) participants who considered alcohol reduction pursued the activity, and 14 of 24 (58%) women who considered exercise followed through. Participants listed fear of side effects as the most common barrier to endocrine risk reduction. We also present further steps to be taken to improve the effectiveness of the Breast Health Decisions tool.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在 WISDOM 研究中使用个性化乳腺癌教育工具后开展降低风险活动的验证研究。
降低乳腺癌风险的策略已经得到了很好的验证,但高风险人群在采用这些策略时仍然存在障碍。我们在乳腺癌高危人群中进行了一项研究,以验证虚拟乳房健康决策工具是否会影响参与者开始降低风险活动的意愿,确定采取这些策略的障碍,并了解它是否会影响乳腺癌焦虑。研究样本是 "根据风险措施进行筛查的女性知情者"(WISDOM)临床试验个性化(研究)部分的 318 名参与者。这些参与者在查看工具后填写了一份反馈调查。我们表明,15 名(4.7%)妇女正在服用降低内分泌风险的药物,123 名(38.7%)妇女正在减少酒精摄入量,199 名(62.6%)妇女正在锻炼身体。在对 109 名受访者进行的为期三个月的跟踪调查中,61 名考虑降低内分泌风险的女性中只有 8 人(13.1%)采取了这一措施。相比之下,16 位考虑减少饮酒的受访者中有 11 位(68%)坚持了这项活动,24 位考虑锻炼的女性中有 14 位(58%)坚持了这项活动。参与者将对副作用的恐惧列为降低内分泌风险最常见的障碍。我们还介绍了为提高乳房健康决策工具的有效性而需采取的进一步措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
NPJ Breast Cancer
NPJ Breast Cancer Medicine-Pharmacology (medical)
CiteScore
10.10
自引率
1.70%
发文量
122
审稿时长
9 weeks
期刊介绍: npj Breast Cancer publishes original research articles, reviews, brief correspondence, meeting reports, editorial summaries and hypothesis generating observations which could be unexplained or preliminary findings from experiments, novel ideas, or the framing of new questions that need to be solved. Featured topics of the journal include imaging, immunotherapy, molecular classification of disease, mechanism-based therapies largely targeting signal transduction pathways, carcinogenesis including hereditary susceptibility and molecular epidemiology, survivorship issues including long-term toxicities of treatment and secondary neoplasm occurrence, the biophysics of cancer, mechanisms of metastasis and their perturbation, and studies of the tumor microenvironment.
期刊最新文献
Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer. Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets. Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial. Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases. Sequence of therapy impact on older women with comorbidities and triple-negative or HER2-positive breast cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1